Uchihara Masakatsu, Izumi Namiki
Division of Gastroenterology and Hepatology, Musashino Red-Cross Hospital.
Nihon Rinsho. 2006 Jun;64(6):1133-8.
Nonalcoholic fatty liver disease (NAFLD) encompasses a histological spectrum ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) that may progress eventually to cirrhosis. Any clinically useful serum biomarkers have never been reported to distinguish patients with NASH from those with simple steatosis. The serum CRP concentration, formerly used as a marker of acute-phase reaction, has been revealed to be a strong predictor of coronary event after the introduction of the high-sensitivity assay method. Patients with metabolic syndrome also have been reported to have higher high-sensitivity CRP(hs-CRP) concentration. We showed patients with more active form of NASH (grade2-3) have higher concentration of hs-CRP than those with quiescent form of NASH (grade1) or simple steatosis. hs-CRP may be a promising biomarker for screening of NASH, a hepatic manifestation of metabolic syndrome.
非酒精性脂肪性肝病（NAFLD）涵盖了从单纯性脂肪变性到非酒精性脂肪性肝炎（NASH）的组织学范围，后者最终可能进展为肝硬化。尚未有任何临床上有用的血清生物标志物被报道可用于区分NASH患者和单纯性脂肪变性患者。血清CRP浓度以前用作急性期反应的标志物，在引入高灵敏度检测方法后，已被证明是冠状动脉事件的强预测指标。据报道，代谢综合征患者的高灵敏度CRP（hs-CRP）浓度也较高。我们发现，具有更活跃形式的NASH（2-3级）患者的hs-CRP浓度高于静止形式的NASH（1级）或单纯性脂肪变性患者。hs-CRP可能是一种有前景的生物标志物，用于筛查代谢综合征的肝脏表现NASH。
